Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GALNON TFA(475115-35-6(free base)) 是一种新型非肽甘丙肽受体激动剂(GAL1 和 GAL2,Ki 分别为 11.7 和 34.1 μM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,290 | 现货 | ||
2 mg | ¥ 1,930 | 现货 | ||
5 mg | ¥ 2,920 | 现货 | ||
10 mg | ¥ 4,320 | 现货 | ||
25 mg | ¥ 6,890 | 现货 | ||
50 mg | ¥ 9,330 | 现货 | ||
100 mg | ¥ 12,500 | 现货 | ||
500 mg | ¥ 25,200 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,750 | 现货 |
产品描述 | Galnon is a novel non-peptide galanin receptor agonist (GAL1 and GAL2 with Ki of 11.7 and 34.1 μM respectively). |
体内活性 | Galnon stimulated insulin release potently in isolated Wistar rat islets; 100 microM of the compound increased the release 8.5 times (p<0.001) at 3.3 mM and 3.7 times (p<0.001) at 16.7 mM glucose. Also in islet perifusions, galnon augmented several-fold both acute and late phases of insulin response to glucose. Furthermore, galnon stimulated insulin release in GK rat islets. These effects were not inhibited by the presence of galanin or the galanin receptor antagonist M35. The stimulatory effects of galnon were partly inhibited by the PKA and PKC inhibitors, H-89 and calphostin C, respectively, at 16.7 but not 3.3 mM glucose. In both Wistar and GK rat islets, insulin release was stimulated by depolarization of 30 mM KCl, and 100 microM galnon further enhanced insulin release 1.5-2 times (p<0.05). Cytosolic calcium levels, determined by fura-2, were increased in parallel with insulin release, and the L-type Ca2+-channel blocker nimodipine suppressed insulin response to glucose and galnon[1].galnon, a GAL receptor agonist, may enhance osteoclastic bone resorption in OVX rats. Although galnon reduced bone volume, biomechanical testing revealed that bone of galnon-treated animals was mechanically superior per unit area. Taken together, galnon simultaneously improves the intrinsic quality of cortical bone whilst stimulating osteoclastic activity in the OVX rat model[2]. |
动物实验 | OVX rats were treated with either vehicle or galnon for 6 weeks via mini-osmotic pumps. Plasma osteocalcin concentrations, osseous cell gene expression, morphological and biomechanical properties of the skeleton were compared between the two groups[2] |
分子量 | 92.84 |
分子式 | C42H47F3N4O8 |
CAS No. | T8559 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (269.28 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 10.7712 mL | 53.8561 mL | 107.7122 mL | 269.2805 mL |
5 mM | 2.1542 mL | 10.7712 mL | 21.5424 mL | 53.8561 mL | |
10 mM | 1.0771 mL | 5.3856 mL | 10.7712 mL | 26.928 mL | |
20 mM | 0.5386 mL | 2.6928 mL | 5.3856 mL | 13.464 mL | |
50 mM | 0.2154 mL | 1.0771 mL | 2.1542 mL | 5.3856 mL | |
100 mM | 0.1077 mL | 0.5386 mL | 1.0771 mL | 2.6928 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GALNON TFA(475115-35-6(free base)) T8559 GPCR/G Protein Neuroscience Neuropeptide Y Receptor GALNON TFA(475115356(free base)) GALNON TFA(475115 35 6(free base)) Inhibitor inhibitor inhibit